Intuitive Surgical reports a surprisingly strong first quarter

Intuitive Surgical reports a surprisingly strong first quarter

Last week Intuitive Surgical (ISRG) surprised everybody, including, apparently, management. Intuitive Surgical’s first-quarter revenue grew 14% year-over-year to $1.7 billion. (Wall Street was expecting $1.6 billion.) Surgical procedures performed using the company’s da Vinci system, rose 26% year-over-year, well above expectations for 15% growth. And the company raised guidance for global procedure growth to 18% to 21% from the prior guidance of 12% to 16%.

Selling Intuitive Surgical out of Jubak Picks as it holds above target price

Selling Intuitive Surgical out of Jubak Picks as it holds above target price

Today, April 28, I’m selling Intuitive Surgical out of my Jubak Picks Portfolio with a 9.39% gain since February 15. I think the shares are fully valued here (or perhaps over-valued if there is such a thing anymore in this market) and I’d like to have some more cash just in case”something” creates a little volatility in the financial markets.

Intuitive Surgical earnings surprise as recovery from pandemic faster than expected

Intuitive Surgical earnings surprise as recovery from pandemic faster than expected

Yesterday, April 20, after the market close Intuitive Surgical (ISRG) reported first quarter GAAP earnings of $3.51 a share, $1.47 a share above Wall Street estimates. Non-GAAP earnings of $3.52 were 89 cents a share above analyst expectations. Revenue for the quarter climbed to $1.3 billion, up 18% from the first quarter of 2020. In 2020 sales of the company’s robotic surgery systems, dropped to $4.4 billion from $4.5 billion in 2019 as hospitals halted elective surgeries during the pandemic. I added the shares to my Jubak Picks Portfolio on February 15, 2021 on expectations with in a post-vaccine global economy sales of its da Vinci Surgical Systems would rebound strongly. In the first quarter the company shipped 298 de Vinci systems versus 237 in the first quarter of 2020. As of 3:45 p.m. New York time today, Intuitive Surgical share were up 9.50% to $888.10. That exceeds my target of $860 a share and I’ll be looking to sell the shares sometime in the next couple of weeks after I’ve received the full benefit from a positive earnings season for BIG TECH stocks.

Special Report: Profit and Protect–What you need to know about stock market stages for 2021–Stage 2 of 3: My rules for selling in the “When you win, you lose market” (and sells of ILMN, CTVA, WST, and VMW)

Special Report: Profit and Protect–What you need to know about stock market stages for 2021–Stage 2 of 3: My rules for selling in the “When you win, you lose market” (and sells of ILMN, CTVA, WST, and VMW)

On to Stage #2 in my Special Report: “Profit and Protect–What you need to know about stock market stages for 2021. And to my rules for the sells and hedges in Stage #2 for 2021: When you win, you lose. (I just posted sells for ILMN, CTVA, WST and VMW)

Special Report: Profit and Protect–What you need to know about stock market stages for 2021–Updated Part 1 and 2 of 3 with my 10 picks to buy now, my first 4 sells, and my first 2 hedges

Special Report: Profit and Protect–What you need to know about stock market stages for 2021–Updated Part 1 and 2 of 3 with my 10 picks to buy now, my first 4 sells, and my first 2 hedges

2021 is shaping up as an especially challenging year for investors. Much, much more challenging than 2020. I don’t think we can count on this rally running uninterrupted through the year. That would be simple, wouldn’t it? We’d all know how to profit from that scenario. And I don’t think the market is about to drop off a cliff from its current record highs. That would be traumatic. But, still, we do know how to protect a portfolio in that scenario. And even how to profit from a prolonged plunge–if we can bring ourselves to place those short and Put Options bets. Instead 2021 is likely to be one of those years with a Rally Stage and then a correction (or “something”) to be followed by a last quarter of 2021 that is, at this moment, close to completely unpredictable. That would make 2021 one of those years that gives investors a chance to be wrong several times over, to botch timing on the upside and the downside, and to let emotions power some really bad investment moves. I don’t pretend that I’ve got this year’s market stages down perfectly–although I think the outlines for the first two stages for 2021 are pretty clear. I don’t imagine that I’ve got the timing for navigating these stages clocked perfectly–although I do think I understand “generally” when the market is likely to switch gears. And that lets me lay out for you a likely pattern for 2021 and to suggest stocks and ETFs to use to navigate this year. Part of the point in getting as specific as I can at this point isn’t that I expect that I’ve got everything right, but to lay out concrete markers that will let you and me adjust portfolios as the year progresses. I’m dividing this Special Report into three parts.

Intuitive Surgical Pick #10 for my new Millennial Portfolio (for investors who have more time than money); also adding it to Jubak Picks

Intuitive Surgical Pick #10 for my new Millennial Portfolio (for investors who have more time than money); also adding it to Jubak Picks

In my first 10 (actually to be 11 since I’ve got another pick up my sleeve) picks for my new Millennial Portfolio (for investors who have more time than money) I’ve been on the hunt for shares of companies with long, long revenue and earnings growth runways ahead of them, with short-term catalysts that might produce enough of a gain in the near term to keep investors on board for the long run, and some bad news in the present that been negative enough to take a bite of the stock price. Today, February 15, I’m adding Intuitive Surgical to my Millennial Portfolio and to my Jubak Picks Portfolio

Special Report: 10 Stocks to Beat Amazon–Part 1 Why Amazon is such a tough stock to beat and why my first pick Illumina jumps the hurdle; second pick Intuitive Surgical, third pick is ASML, fourth pick is Seattle Genetics, fifth pick is Danaher, sixth pick Thermo Fisher

Special Report: 10 Stocks to Beat Amazon–Part 1 Why Amazon is such a tough stock to beat and why my first pick Illumina jumps the hurdle; second pick Intuitive Surgical, third pick is ASML, fourth pick is Seattle Genetics, fifth pick is Danaher, sixth pick Thermo Fisher

Amazon (AMZN). Maybe you've heard of it. It's been one of the great stocks of the best--well, however long. As of June 15, Morningstar puts the stock's 15-year return at an average of 33.11% a year. That's the kind annual performance that you need to show to be a...